Welcome to our dedicated page for Gohealth SEC filings (Ticker: GOCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GoHealth, Inc. filings document the public-company record for a Medicare-focused digital health and insurance marketplace. Its 8-K reports cover operating results, financial-condition updates, capital and credit arrangements, and material agreements, including secured term-loan financing involving GoHealth subsidiaries such as Norvax, LLC.
Proxy and governance filings describe annual meeting proposals, director elections, executive compensation votes, incentive-plan matters, auditor ratification, board appointments, committee roles, and stockholder voting results. The filing record also includes capital-structure disclosures, risk and liquidity context tied to Medicare Advantage conditions, and Nasdaq continued-listing compliance notices for GOCO common stock.
GoHealth reported mixed results for the quarter ended June 30, 2025. Net revenues declined to $94.0 million from $105.9 million a year earlier, while year-to-date revenues increased to $315.0 million from $291.5 million. The company recorded a significant $53.0 million indefinite-lived trade names impairment that, together with higher operating expenses, drove an operating loss of $99.4 million for the quarter and a net loss attributable to GoHealth of $54.3 million (basic loss per Class A share $5.10).
Liquidity and capital structure changed materially: cash and cash equivalents were $35.6 million, total long-term debt rose to $560.0 million and commissions receivable remained substantial at $996.6 million. Management states that after entering a Superpriority Credit Agreement and amendments, management believes available liquidity is sufficient to cover operating requirements for the next 12 months, alleviating prior substantial doubt about going concern.
Blue Torch Capital LP and Kevin Genda report beneficial ownership of 1,445,181 shares of GoHealth, Inc. Class A common stock, representing 9% of the class. The filing states these shares were issued to lenders and their affiliates as consideration and a condition to lender participation in Amendment No.14 to the Issuer's Credit Agreement dated August 6, 2025. The Reporting Persons disclose shared voting and shared dispositive power over these shares and report no sole voting or dispositive power.
The statement identifies Blue Torch as an investment manager and Mr. Genda as the managing member of the general partner. The percentage calculation references 11,222,135 shares outstanding as of August 5, 2025 plus 4,766,219 shares issued on August 6, 2025. No other transactions in the past 60 days are reported.
Amendment No. 5 to the Schedule 13D discloses a Superpriority Senior Secured Term Loan package totaling $115.0 million for Norvax, LLC, comprised of $80.0 million new-money term loans (with $40.0 million funded immediately and $40.0 million as delayed-draw availability) and $35.0 million of roll-up term loans from conversion of existing Class A revolving loans.
The related amendment to the existing credit agreement terminates Class A-1 and Class A revolving commitments, extends the maturity of remaining Class A revolving loans to August 5, 2029, permits pay-in-kind interest with an accrual rate of Adjusted Term SOFR + 8.00% (with at least Adjusted Term SOFR + 4.50% paid in cash), and waives amortization of existing term loans until December 31, 2026. As consideration, the issuer issued 4,766,219 Class A shares to certain lenders, representing 19.99% of the combined issued and outstanding Class A and Class B common stock, with customary registration rights. The Board appointed three new directors and three existing directors resigned.
Reporting Persons disclose beneficial ownership stakes in Class A common stock: CCP III Cayman GP Ltd. 9,566,028 shares (45.0%), CB Blizzard Holdings C 1,467,653 shares (9.2%), Centerbridge Associates III, L.P. and related entities 2,712,197 shares (17.1%), Blizzard Aggregator, LLC 5,386,178 shares (25.3%), and Jeffrey H. Aronson 9,566,028 shares (45.0%). The filing states the group may be deemed to collectively beneficially own 16,007,486 shares, approximately 58.3% of 15,881,344 reported Class A shares outstanding.
Kotte Vijay, identified as a director and Chief Executive Officer of GoHealth, Inc. (GOCO), was granted 218,551 restricted stock units on 08/07/2025 under a First Amendment to his employment agreement. The restricted stock units vest in three annual installments, with the first installment vesting on 08/07/2026. Following the reported transaction, the filing shows beneficial ownership of 1,347,396 shares of Class A common stock, which includes 1,798 shares purchased under the company’s Employee Stock Purchase Plan on 06/30/2025. The filing also corrects prior disclosures by reducing previously reported holdings by 94,444 shares that were subject to unmet performance conditions.
GoHealth, Inc. (GOCO) Form 3 filed for Alan Jeffrey Carr. The filing records Mr. Carr as a director with an event date of 08/06/2025 and states that no securities are beneficially owned by the reporting person. The filing includes Exhibit 24 (Power of Attorney) and was signed by an attorney-in-fact on 08/08/2025.
Timothy R. Pohl submitted an initial Form 3 as a director of GoHealth, Inc. (GOCO). The filing discloses that he does not beneficially own any securities of the issuer. The form lists his business address and attaches an Exhibit 24 Power of Attorney. This is an informational ownership disclosure required by Section 16 and does not report any shares or derivative holdings.
William L. Transier filed an Initial Form 3 reporting his relationship to GoHealth, Inc. (GOCO) as a director. The event date is 08/06/2025. The filing states that no securities are beneficially owned by the reporting person and includes Exhibit 24 (Power of Attorney). The form lists a Chicago address for the reporting person and is signed on behalf of Transier by an attorney-in-fact on 08/08/2025.
On 6 Aug 2025, GoHealth (GOCO) executed a series of financing and governance actions aimed at improving near-term liquidity and extending maturities.
- $115 m super-priority term loan: $80 m in new money ($40 m funded now; $40 m delayed-draw before Dec-25) plus $35 m roll-up of existing revolver. Rate: Term SOFR + 5.50 % (3 % floor) or ABR + 4.50 % (4 % floor) plus a cash MOIC premium of up to 2.0×. Maturity: 5 Aug 2029. First-lien on substantially all assets and senior to the existing credit facility.
- Covenants: Weekly minimum liquidity starts at $5 m (Oct-25) and rises to $30 m (Sep-26). Borrower barred from prepaying legacy Class A loans until super-priority debt is fully repaid.
- Amendment No. 14: Terminates unused revolver commitments, extends remaining Class A revolver maturity to 2029, allows part PIK interest (Adj. SOFR + 8 %) and waives term-loan amortization until 31 Dec 2026. Leverage and asset coverage covenants removed.
- Equity issuance: Lenders received 4,766,219 Class A shares (~19.99 % of pre-transaction shares) in a private placement.
- Board changes: Three directors appointed (Timothy R. Pohl, Alan J. Carr, William L. Transier); three directors resigned. A new Transformation Committee will evaluate strategic alternatives.
The package provides fresh capital and maturity relief but at high cost and with substantial dilution and restrictive covenants.
GoHealth (Nasdaq: GOCO) filed an 8-K disclosing the results of its 2025 Annual Meeting of Stockholders held on June 18, 2025.
Shareholders elected three Class II directors—Brandon M. Cruz (17,218,021 FOR), Alan Wheatley (17,932,740 FOR) and Abhiraj R. Modi (17,619,537 FOR)—to serve until the 2028 meeting. Ernst & Young LLP was ratified as independent auditor with 21,544,738 FOR and only 557,922 AGAINST. The non-binding say-on-pay resolution passed (17,026,293 FOR; 992,227 AGAINST), and shareholders approved an amendment to the 2020 Incentive Award Plan (16,755,619 FOR; 1,287,341 AGAINST).
No financial performance metrics, strategic updates, or other material events were included in the filing.